Claris Lifesciences Limited

clarislifesciences.com

Claris Lifesciences Limited is a multi-business enterprise and the Holding Company of Claris Injectables, a wholly-owned subsidiary dealing in Specialty Injectables business, collectively “Claris”; and ‘Claris Otsuka’, a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India & Emerging Markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

MODEL N AND PFIZER INNOVATE DRUG PRICE TRANSPARENCY REPORTING

Model N, Inc. | August 04, 2022

news image

Model N, Inc. the leader in revenue optimization and compliance, announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs. Transparency Talks will bring together leaders from Model N, Pfizer and Global Pricing Innovations (GPI) to explore state drug pricing laws and regulations, as well as facilitate a discussion on trends, best practices and innovative approaches th...

Read More

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

news image

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

news image

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More
news image

BUSINESS INSIGHTS

MODEL N AND PFIZER INNOVATE DRUG PRICE TRANSPARENCY REPORTING

Model N, Inc. | August 04, 2022

Model N, Inc. the leader in revenue optimization and compliance, announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs. Transparency Talks will bring together leaders from Model N, Pfizer and Global Pricing Innovations (GPI) to explore state drug pricing laws and regulations, as well as facilitate a discussion on trends, best practices and innovative approaches th...

Read More
news image

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More
news image

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More
news image

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More